COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.

Detalles Bibliográficos
Publicado en:Lancet Vol. 360; no. 9339; pp. 1071 - 1074
Autores principales: Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR
Formato: letter research tables/charts Journal Article
Publicado: Lancet 10/5/2002
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106800298&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106800298
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01406736
        LAN
      jtl: Lancet
      issn: 01406736
      maglogo: N
    pubinfo:
      dt: 10/5/2002
      vid: 360
      iid: 9339
      pid: 1297
      pub: Lancet
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        106800298
        106800298
        2003020673
        10.1016/s0140-6736(02)11131-7
        NLM12383990
        106800298
      ppf: 1071
      ppct: 3
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
      aug:
        au:
          Ray WA
          Stein CM
          Daugherty JR
          Hall K
          Arbogast PG
          Griffin MR
        affil: Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232; Wayne.Ray@mcmail.vanderbilt.edu
      sug:
        subj:
          Antiinflammatory Agents, Non-Steroidal Adverse Effects
          Coronary Disease Risk Factors
          Cox-2 Inhibitors Adverse Effects
          Aged
          Antiinflammatory Agents, Non-Steroidal Administration and Dosage
          Coronary Disease Epidemiology
          Cox-2 Inhibitors Administration and Dosage
          Descriptive Statistics
          Drug Monitoring
          Medicaid
          Middle Age
          Prospective Studies
          Regression
          Retrospective Design
          Tennessee
          Funding Source
          Human
          Aged: 65+ years
          Middle Aged: 45-64 years
      pubtype: Academic Journal
      doctype:
        letter
        research
        tables/charts
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N